Back

Variant Subpopulations in Nitroimidazole Resistance Genes in DELIBERATE trial participants

Naufal, F.; Folkerts, M. L.; Limberis, J. D.; Streicher, E. M.; Nalyvayko, A.; Maartens, G.; Dooley, K. E.; Warren, R.; Engelthaler, D. M.; Metcalfe, J. Z.

2025-11-07 infectious diseases
10.1101/2025.09.15.25335512 medRxiv
Show abstract

Targeted next-generation sequencing (tNGS) enables rapid detection of drug resistance in Mycobacteriumtuberculosis (Mtb), including minor variants that may indicate emerging resistance. We applied tNGS to isolates from 34 (of 49 eligible) participants in a randomized trial of bedaquiline (BDQ) and delamanid (DLM) co-administration for multidrug-resistant TB (MDR-TB). We detected baseline nonsynonymous variants in the nitroimidazole resistance genes fgd2 and ddn (BDQ arm) and fbiB (DLM arm) among 2/12 and 2/12 patients, respectively, and emergent subpopulations with nonsynonymous variants in fbiB, fbiC, and ddn as early as week 1 in 3/34 patients. These findings demonstrate that variants in nitroimidazole resistance genes may be present in the absence of drug exposure, and that tNGS can effectively track variant emergence during MDR-TB treatment.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.